Actively Recruiting
Phase 2 Study of Three Different Doses of Intravenous Telisotuzumab Vedotin in Adults With Previously Treated c-Met Overexpressing Non-Small Cell Lung Cancer
Led by AbbVie · Updated on 2026-07-24
150
Participants Needed
80
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Non-small cell lung cancer NSCLC is a condition where cancer cells grow uncontrollably in the lung tissues. This study evaluates the safety of an investigational drug called telisotuzumab vedotin in adults with previously treated NSCLC that overexpresses c-Met. The trial also monitors changes in disease activity and side effects over time. Participants will be randomly assigned to receive one of three different doses of telisotuzumab vedotin through intravenous IV infusion. Each dose group receives treatment as part of a study lasting up to three years. The study involves approximately 150 adults with c-Met positive NSCLC across many sites worldwide. Throughout the study, participants will attend regular hospital or clinic visits where they undergo medical assessments, blood tests, and complete questionnaires to evaluate how the drug affects their disease and any side effects experienced. The study measures treatment-related adverse events, disease response, and survival outcomes over the three-year period.
CONDITIONS
Brief Title
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
